EUVIMEDEUVIMED entdecken
Multizentrische Studie

Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database

Diana Kim, Sarah Blocker, Courtney C Cavalieri, Sabrina Cannon, Amanda S Cass, Alexander Olinger, Bryce Bortka, Beth Gustafson, Allison Schepers, Jacob Hobbs, Lauren Blackwell, Kori Holman und 9 weitere

Clinical Lung Cancer · 2026

DOI: 10.1016/j.cllc.2026.01.007 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2026. Verfasst von Diana Kim und 20 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, The University of Kansas Cancer Center, Westwood, KS. Hauptthemen laut MEDLINE: Small Cell Lung Carcinoma, Lung Neoplasms, Chemoradiotherapy, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Small cell lung cancer (SCLC) is an aggressive malignancy in which radiotherapy remains integral across both limited and extensive stages (ES-SCLC). Tarlatamab has shown improved survival versus chemotherapy and is the preferred second-line therapy. Early tarlatamab studies restricted radiotherapy use limiting knowledge of concurrent use. We evaluated the safety and efficacy of real-world concurrent radiotherapy with tarlatamab in ES-SCLC using the DLL3 PanTUMOR database. METHODS: We performed a multicenter retrospective analysis of adults treated with tarlatamab for ES-SCLC between May 2024 and July 2025. Patients receiving radiotherapy after tarlatamab initiation were assigned to the concurrent radiation arm; others formed the nonradiotherapy (non-RT) arm. The primary endpoint was the rate of grade ≥ 3 adverse events attributed to radiotherapy. Secondary endpoints included overall survival (OS), progression-free survival (PFS), tumor regression at irradiated sites, discontinuation due to adverse events, and maximum CRS or ICANS grade. RESULTS: Among 109 patients (23 concurrent RT, 86 non-RT), baseline characteristics were balanced. Stereotactic radiotherapy was most common (56.5%), predominantly to the brain. Only 1 patient (4.3%) experienced grade ≥ 3 radiotherapy-related toxicity after whole-brain radiotherapy. Median OS was not reached in the concurrent RT arm versus 7.5 months in non-RT (P = .155); median PFS was 4.6 versus 3.1 months (P = .606). Tumor regression occurred in 5 of 6 evaluable patients (83.3%). No delayed CRS or ICANS were observed after the tarlatamab step-up phase. CONCLUSIONS: Concurrent radiotherapy with tarlatamab is safe, with low severe toxicity, frequent local tumor response, and a trend toward improved OS, supporting further study in ES-SCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Small Cell Lung CarcinomaLung NeoplasmsChemoradiotherapyAntineoplastic AgentsHumansFemaleRetrospective StudiesMaleAgedMiddle AgedNeoplasm StagingAged, 80 and overSurvival RateMembrane ProteinsDatabases, FactualIntracellular Signaling Peptides and ProteinsAdultAntibodies, Bispecific

Stichwörter der Autor:innen

Overall survivalRTRadiationSBRTSCLC

Substanzen

DLL3 protein, humanAntineoplastic AgentsMembrane ProteinsIntracellular Signaling Peptides and ProteinsAMG 757Antibodies, Bispecific

Autor:innen und Institutionen

  • Medical Oncology, The University of Kansas Cancer Center, Westwood, KS.
  • Medical Oncology, Huntsman Cancer Institute, Salt Lake City, UT.
  • Medical Oncology, Vanderbilt University Medical Center, Nashville, TN.
  • Medical Oncology, Nebraska Medicine, Omaha, NE.
  • Saint Luke's Hospital of Kansas City, Kansas City, MO.
  • Medical Oncology, University of Michigan Health, Ann Arbor, MI.

Zitieren

APA

Kim, D., Blocker, S., Cavalieri, C. C., Cannon, S., Cass, A. S., Olinger, A., Bortka, B., Gustafson, B., Schepers, A., Hobbs, J., Blackwell, L., Holman, K., Widman, W., Quick, A., Grauer, D., Lekkala, M. R., Huang, C., Neupane, P., Zhang, J., …, & Schieber, T. (2026). Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.01.007

Vancouver

Kim D, Blocker S, Cavalieri CC, Cannon S, Cass AS, Olinger A, et al. Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database. Clinical Lung Cancer. 2026. doi:10.1016/j.cllc.2026.01.007

BibTeX
@article{Kim2026,
  author = {Kim, Diana and Blocker, Sarah and Cavalieri, Courtney C and Cannon, Sabrina and Cass, Amanda S and Olinger, Alexander and Bortka, Bryce and Gustafson, Beth and Schepers, Allison and Hobbs, Jacob and Blackwell, Lauren and Holman, Kori and Widman, Wilder and Quick, Austin and Grauer, Dennis and Lekkala, Manidhar Reddy and Huang, Chao and Neupane, Prakash and Zhang, Jun and Mullangi, Sanjana and Schieber, Timothy},
  title = {Outcomes of Concurrent Radiotherapy With Tarlatamab in Extensive-Stage Small Cell Lung Cancer From the DLL3 PanTUMOR Database},
  journal = {Clinical Lung Cancer},
  year = {2026},
  doi = {10.1016/j.cllc.2026.01.007}
}
Kostenlos starten →